St. Jude Medical to pay $3.7 million to settle federal kickbacks beef

STJ logo

St. Jude Medical Inc. (NYSE:STJ) and a pair of hospitals in the Midwest agreed to pony up $4 million to settle a federal lawsuit accusing the device maker of providing illegal rebates to the healthcare providers.

Whistleblower Jerry Hudson sued the Minneapolis-based firm in 2006 in the U.S. District Court for Northern Ohio, accusing the company of instituting kickback schemes to increase business from doctors and hospitals, according to court documents. A regional sales manager from February 2004 to September 2005, when he was fired, Hudson accused St. Jude of terminating him because of his objections to the alleged schemes.

The lawsuit alleges that the company regularly offered to support research in exchange for regaining accounts it had lost or for winning new business, making offers to the Cleveland Clinic and University Hospitals of Cleveland in exchange for increased pacemaker and implantable cardiac defibrillator buys. Company sales reps were expected to subsidize the research via reductions to their sales commissions. St. Jude also allegedly tried to influence individual physicians with consulting offers for "advising and consulting" and letting STJ sales reps view surgeries.

In one case, University Hospitals agreed to make a $900,000 purchase "in exchange for the placement of [cardiac mapping] research equipment, according to the lawsuit. UH also allegedly took part in "back-end" rebate plans that gave discounts on previously purchased devices and/or for commitments to large buys. In March 2005, the hospital allegedly took in $14,475 in back-end rebates for devices it bought during the fourth quarter of 2004.

St. Jude also tried to "drive increased CRM units" with the Cleveland Clinic, pushing the provider to commit to implanting one ICD a day, the lawsuit alleged. In another alleged ploy, St. Jude propsoed a "rapid rebate" to the Cleveland Clinic Foundation, offering a 3 percent rebate on minimum-quantity orders from the previous quarter and an additional rebate for implanting devices from that order in the current quarter. In 2005, the CCF took in $186,000 in incentives from St. Jude, according to court documents.

If customers refused to commit to the alleged schemes, St. Jude threatened to remove the donated research equipment, according to the lawsuit.

Parma Community General Hospital, which agreed to pay $40,000 for its part in the case, agreed to a rapid rebate program that earned it $400 per ICD if the device was implanted within 60 days of ordering and if the hospital agreed to make another bulk order before the end of the quarter. Norton Healthcare of Louisville, Ky., agreed to a $133,300 settlement for its role in the alleged schemes.

Hudson accused the company of firing him after he objected to the alleged practices. His share of the settlement of the so-called "qui tam" whistleblower suit amounts to $640,050, according to a U.S. Dept. of Justice press release. In May, the DOJ

It’s not the first legal trouble for St. Jude. In May, the DOJ demanded documents about its implantable cardiac defibrillator business, according to a regulatory filing. The “civil investigative demand” sought documents and “sets forth interrogatories” about “various indications for ICDs and a National Coverage Decision issued by Centers for Medicare and Medicaid Services,” according to the filing. St. Jude said at the time that it believed its major competitors were served with similar demands and that it’s cooperating with the investigation.

And the Food & Drug Administration warned the company last month, citing the device maker for improperly promoting its Epicor cardiac ablation catheter system.

St. Jude said in a prepared statement that it “does not admit liability or wrongdoing. The allegations centered on small, isolated product rebates that the company paid more than five years ago. The company entered into a settlement agreement in order to avoid the potential costs and risks associated with litigation.”

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply